– USA, MA – Hologic, Inc. (Nasdaq: HOLX) announced today that Christopher J. Coughlin has joined the Company’s Board of Directors. Mr. Coughlin was elected to the Board at the Company’s 2016 Annual Meeting of Stockholders, along with nine existing Directors who were re-elected.
Mr. Coughlin, who in December was named “Director of the Year” by the National Association of Corporate Directors, has extensive senior leadership experience, including as the former Chief Financial Officer of Tyco International. He has held executive operating and financial positions at the Interpublic Group, Pharmacia and Nabisco International. Mr. Coughlin currently serves on the boards of Allergan (formerly Actavis), Alexion Pharmaceuticals and Dun & Bradstreet, where he is Chairman of the Board. He previously served on the boards of Covidien, Dipexium Pharmaceuticals, Forest Laboratories, the Interpublic Group, Monsanto and Perrigo.
“It is a pleasure to welcome Chris to Hologic’s Board,” said Steve MacMillan, the Company’s Chairman, President and Chief Executive Officer. “He is a proven business leader who brings a strong track record of value creation. His depth of experience in executive leadership roles within complex corporate organizations, his financial background, and his experience on public company boards will contribute critical insights in Hologic’s efforts to generate sustainable growth and shareholder value.”
About Hologic
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company’s core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
